Cabaletta Bio, Inc.: T. Rowe Price Investment Management, Inc. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
T. Rowe Price Investment Management amended its Schedule 13G filing on Cabaletta Bio, disclosing a revised passive stake in the clinical-stage cell therapy developer. The filing, submitted under SEC accession number 0001897612-26-000706, updates the asset manager's previously reported ownership position in the company. Schedule 13G amendments are typically triggered when an investor's beneficial ownership crosses or adjusts past the 5% threshold, making the disclosure a signal of institutional positioning in the small-cap biotech. Investors will watch for the specific share count and percentage in the amended filing to gauge whether T. Rowe Price added to or trimmed its Cabaletta holding. Cabaletta Bio focuses on engineered T cell therapies for autoimmune diseases, and its share price often reacts to institutional ownership changes and clinical trial updates.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Cabaletta Bio, Inc., T. Rowe Price Investment Management, Inc.